Business Description
Tianjin Lisheng Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000NJ9
Share Class Description:
SZSE:002393: Class ACompare
Compare
Traded in other countries / regions
002393.China IPO Date
2010-04-23Description
Tianjin Lisheng Pharmaceutical Co Ltd manufactures and sells tablet medicine, capsule medicine, pill, freeze-dry powder injection, liquid injection and raw material medicine.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 24.56 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.42 | |||||
| Interest Coverage | 51.04 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.64 | |||||
| Beneish M-Score | -2.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.8 | |||||
| 3-Year EBITDA Growth Rate | 68.9 | |||||
| 3-Year EPS without NRI Growth Rate | 245.8 | |||||
| 3-Year Book Growth Rate | 4.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.72 | |||||
| 9-Day RSI | 40.96 | |||||
| 14-Day RSI | 43.31 | |||||
| 6-1 Month Momentum % | 10.86 | |||||
| 12-1 Month Momentum % | -3.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.01 | |||||
| Quick Ratio | 3.7 | |||||
| Cash Ratio | 3.04 | |||||
| Days Inventory | 135.53 | |||||
| Days Sales Outstanding | 57.05 | |||||
| Days Payable | 55.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.55 | |||||
| Dividend Payout Ratio | 0.74 | |||||
| Forward Dividend Yield % | 3.55 | |||||
| 5-Year Yield-on-Cost % | 3.11 | |||||
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | 3.38 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.64 | |||||
| Operating Margin % | 7.85 | |||||
| Net Margin % | 14.89 | |||||
| FCF Margin % | 13.07 | |||||
| ROE % | 3.86 | |||||
| ROA % | 3.2 | |||||
| ROIC % | 2.78 | |||||
| 3-Year ROIIC % | 205.44 | |||||
| ROC (Joel Greenblatt) % | 21.55 | |||||
| ROCE % | 4.26 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.8 | |||||
| PE Ratio without NRI | 20.74 | |||||
| Shiller PE Ratio | 28 | |||||
| Price-to-Owner-Earnings | 33.53 | |||||
| PEG Ratio | 2.96 | |||||
| PS Ratio | 3.37 | |||||
| PB Ratio | 0.87 | |||||
| Price-to-Tangible-Book | 0.92 | |||||
| Price-to-Free-Cash-Flow | 26.23 | |||||
| Price-to-Operating-Cash-Flow | 20.58 | |||||
| EV-to-EBIT | 10.11 | |||||
| EV-to-EBITDA | 10.11 | |||||
| EV-to-Revenue | 1.75 | |||||
| EV-to-FCF | 12.83 | |||||
| Price-to-Projected-FCF | 0.84 | |||||
| Price-to-Median-PS-Value | 0.91 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.83 | |||||
| Price-to-Graham-Number | 0.92 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 3.54 | |||||
| Earnings Yield (Greenblatt) % | 9.89 | |||||
| FCF Yield % | 3.8 | |||||
| Forward Rate of Return (Yacktman) % | 22.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tianjin Lisheng Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,265.233 | ||
| EPS (TTM) (Â¥) | 0.737 | ||
| Beta | 0.96 | ||
| Volatility % | 29.38 | ||
| 14-Day RSI | 43.31 | ||
| 14-Day ATR (Â¥) | 0.629662 | ||
| 20-Day SMA (Â¥) | 17.55 | ||
| 12-1 Month Momentum % | -3.82 | ||
| 52-Week Range (Â¥) | 12.614285 - 19.44 | ||
| Shares Outstanding (Mil) | 257.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tianjin Lisheng Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tianjin Lisheng Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tianjin Lisheng Pharmaceutical Co Ltd Frequently Asked Questions
What is Tianjin Lisheng Pharmaceutical Co Ltd(SZSE:002393)'s stock price today?
The current price of SZSE:002393 is ¥16.80. The 52 week high of SZSE:002393 is ¥19.44 and 52 week low is ¥12.61.
When is next earnings date of Tianjin Lisheng Pharmaceutical Co Ltd(SZSE:002393)?
The next earnings date of Tianjin Lisheng Pharmaceutical Co Ltd(SZSE:002393) is .
Does Tianjin Lisheng Pharmaceutical Co Ltd(SZSE:002393) pay dividends? If so, how much?
The Dividend Yield %  of Tianjin Lisheng Pharmaceutical Co Ltd(SZSE:002393) is 3.55% (As of Today), Highest Dividend Payout Ratio of Tianjin Lisheng Pharmaceutical Co Ltd(SZSE:002393) was 15.29. The lowest was 0.16. And the median was 0.47. The  Forward Dividend Yield % of Tianjin Lisheng Pharmaceutical Co Ltd(SZSE:002393) is 3.55%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers